The Bean, Chicago
Whenever the Bean photo pops up then you know it marks the start of the annual meeting of the American Society of Clinical Oncology (ASCO).
Ahead of this year’s abstract data palooza, I thought it would be a nice idea to highlight some of the key sessions of interest and important abstracts within.
There are quite a few new molecules to watch out for in early drug development, plus some important phase 3 trial readouts to consider, especially on the combination front.
It will be hard act to beat or even follow the phase 3 lung cancer clinical trials plenary at AACR18 last month, but here goes…
We have selected 11 key areas that may be useful to watch out for as a starting point ahead of the abstract data dump expected tomorrow at 5pm.
To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Some really intriguing news was announced this morning, with Aduro Biotech issuing a press release on their new global collaboration with Novartis for their “immuno-oncology products derived from its proprietary STING-targeted CDN platform technology.”
Many readers will recall Aduro for its program that inserts genetically engineered lysteria into therapeutics aka the LADD regimen. The lead program, CRS–207, in combination with GVAX Pancreas in pancreatic cancer previously received Breakthrough Therapy designation from the FDA. Their scientific advisers include Drew Pardoll and Frank McCormick, who are immunotherapy and protein pathway specialists, respectively.
The collaboration with Novartis is for a completely different platform based on cyclic dinucleotides (CDNs), which are small molecules that are naturally expressed by bacteria and immune cells and have been recently shown to activate the STING (Stimulator of Interferon Genes) signaling pathway in immune cells.
So what’s the significance of this exciting deal and why does it matter?
To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.